Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 858-864
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.858
Table 1 Baseline characteristics of subjects in studies evaluating response to erlotinib after gefitinib
Ref.YearCountryType of studyNo. of patientsGender (M/F)Smoking status (smokers/NS)Histology (A/S/other)
Garfield[9]2005United StatesCase report11/01/00/0/1
Viswanathan et al[16]2005United StatesCase report51/42/3NA
Walther et al[17]2006United KingdomCase report10/10/11/0/0
Chang et al[18]2007TaiwanCase report11/01/01/0/0
Cho et al[19]2007South KoreaProspective2110/1110/1116/3/2
Gridelli et al[32]2007ItalyCase report30/30/33/0/0
Kim et al[33]2007South KoreaCase report10/10/11/0/0
Costa et al[23]2008United StatesRetrospective187/117/1116/0/2
Lee et al[21]2008South KoreaProspective234/190/2322/0/1
Vasile et al[22]2008ItalyProspective84/41/76/0/2
Wong et al[20]2008SingaporeRetrospective144/101/1310/1/3
Wong et al[34]2008SingaporeCase report10/10/11/0/0
Wu et al[35]2008TaiwanCase report10/10/11/0/0
Katayama et al[36]2009JapanRetrospective72/5NA7/0/0
Sim et al[24]2009South KoreaRetrospective160/160/1616/0/0
Zhou et al[25]2009ChinaProspective2114/710/118/9/4
Wong et al[26]2010ChinaRetrospective212/191/2019/0/2
Asami et al[27]2011JapanRetrospective4213/2914/2842/0/0
Hata et al[29]2011JapanRetrospective12549/7655/70117/NA/8
Masuda et al[37]2011JapanCase report33/0NA3/0/0
Shoji et al[38]2011JapanCase report11/0NA1/0/0
Song et al[39]2011ChinaRetrospective209/115/1518/0/2
Takenaka et al[40]2011JapanCase report10/10/11/0/0
Saito et al[41]2012JapanRetrospective219/129/1219/0/2
Tetsumoto et al[42]2012JapanCase report20/20/22/0/0
Koyama et al[43]2013JapanRetrospective104156/4850/5490/6/8